Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study

NCT02593773 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Friedreich's Ataxia

Interventions

DRUG: Interferon γ-1b

Sponsor

Amgen

Collaborators

[object Object]